The partnership will utilize IsoPlexis' IsoLight automated cell manufacturing platform and Lonza's Cocoon automated cell therapy manufacturing solution to perform end-to-end automation. Notably, IsoLight will perform functional proteomics analysis on cell therapy products created by Cocoon.

IsoLight provides functional characterization of cell therapy products for correlative functional potency, according to IsoPlexis. Meanwhile, Cocoon enables centralized and decentralized manufacturing of novel cell therapies, noted Lonza.

IsoPlexis partners with Columbia for vaccine development
IsoPlexis is partnering with Columbia University's Division of Infectious Diseases to create a vaccine for COVID-19. IsoPlexis' Single-Cell Secretome...

Moderna moves COVID-19 vaccine to late-stage clinical trial
Moderna has finalized phase III clinical study protocols for its mRNA-1273 COVID-19 vaccine candidate in coordination with the U.S. Food and Drug Administration...

Moderna lays out plan for mRNA-1273 vaccine
Moderna released interim clinical data about mRNA-1273, its vaccine candidate against SARS-CoV-2, from the phase I study led by the U.S. National Institute...